This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brunner, M.
Right arrow Articles by Sigal, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunner, M.
Right arrow Articles by Sigal, L. H.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 1998, p. 1074-1080, Vol. 36, No. 4
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Immunoglobulin M Capture Assay for Serologic Confirmation of Early Lyme Disease: Analysis of Immune Complexes with Biotinylated Borrelia burgdorferi Sonicate Enhanced with Flagellin Peptide Epitope

Michael Brunner,1 Stanley Stein,2 Paul D. Mitchell,3 and Leonard H. Sigal1,4,*

Department of Medicine1 Departments of Pediatrics and Molecular Genetics & Microbiology,4 University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Center for Advanced Biotechnology and Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School and Rutgers University, Piscataway, New Jersey2; and Marshfield Laboratories, Marshfield, Wisconsin3

Received 14 August 1997/Returned for modification 8 October 1997/Accepted 8 December 1997

We previously reported on the efficacy of the enzyme-linked immunoglobulin M capture immune complex (IC) biotinylated antigen assay (EMIBA) for the seroconfirmation of early Lyme disease and active infection with Borrelia burgdorferi. In earlier work we identified non-cross-reacting epitopes of a number of B. burgdorferi proteins, including flagellin. We now report on an improvement in the performance of EMIBA with the addition of a biotinylated form of a synthetic non-cross-reacting immunodominant flagellin peptide to the biotinylated B. burgdorferi B31 sonicate antigen source with the avidin-biotinylated peroxidase complex detection system used in our recently developed indirect IgM-capture immune complex-based assay (EMIBA). As in our previous studies, the enzyme-linked immunosorbent assay (ELISA) reactivities of antibodies liberated from circulating ICs (by EMIBA) were compared with those of antibodies in unprocessed serum (antibodies found free in the serum, thus as an IgM-capture ELISA, but not EMIBA, because the antibodies were not liberated from ICs), the sample usually used in standard ELISAs and Western blot assays. The addition of the flagellin epitope enhanced the ELISA signal obtained with untreated sera from many Lyme disease patients but not from healthy controls. In tests with both free antibodies and ICs, with or without the addition of the flagellin epitope to the sonicate, we found the most advantageous combination was IC as the source of antibodies and sonicate plus the flagellin epitope as the antigen. In a blinded study of sera obtained from patients with early and later-phase Lyme disease, EMIBA with the enhanced antigenic preparation compared favorably with other serologic assays, especially for the confirmation of early disease.

* Corresponding author. Mailing address: 1 Robert Wood Johnson Place MEB 484, New Brunswick, NJ 08903-0019. Phone: (732) 235-7704. Fax: (732) 235-7238. E-mail: sigallh{at}umdnj.edu.

Journal of Clinical Microbiology, April 1998, p. 1074-1080, Vol. 36, No. 4
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Brunner, M., Marques, A. R., Hornung, R. L. (2006). Report Refuting Value of Immune Complexes To Diagnose Lyme Disease Is Invalid. CVI 13: 304-306 [Full Text]  
  • Marques, A. R., Hornung, R. L., Dally, L., Philipp, M. T. (2005). Detection of Immune Complexes Is Not Independent of Detection of Antibodies in Lyme Disease Patients and Does Not Confirm Active Infection with Borrelia burgdorferi. CVI 12: 1036-1040 [Abstract] [Full Text]  
  • Brunner, M., Sigal, L. H. (2001). Use of Serum Immune Complexes in a New Test That Accurately Confirms Early Lyme Disease and Active Infection with Borrelia burgdorferi. J. Clin. Microbiol. 39: 3213-3221 [Abstract] [Full Text]  
  • Schriefer, M. E., Dennis, D. T., Gubler, D. J., Hayes, E. B., Johnson, B. J. B., Chu, M. C., Schutzer, S. E., Holland, B., Reid, P., Coyle, P. K. (2000). Serologic Testing for Lyme Disease. JAMA 284: 695-696 [Full Text]  
  • Chattopadhyay, A., Nam, C., Dragomir-Daescu, D. (1999). Delamination Modeling and Detection in Smart Composite Plates. Journal of Reinforced Plastics and Composites 18: 1557-1572 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»